BULERIA. Repositorio Institucional de la Universidad de León
Publicación
Artículo científico (JournalArticle)
A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non‐Alcoholic Fatty Liver Disease
[EN] Scope: Gut microbiota contributes to non-alcoholic fatty liver disease (NAFLD) pathogenesis by multiple mechanisms not yet completely understood. Novel differential features between germ-free mice (GFm) transplanted with protective or non-protective cecal microbiota against NAFLD are investigated. Methods and results: Gut microbiota composition, plasma, and fecal bile acids (BAs) and liver mRNAs are quantified in GFm recipients from four donor mice differing in NAFLD severity (control diet, high-fat diet [HFD]-responder, HFD-non-responder, and quercetin-supplemented HFD). Transplanted GFm are on control or HFD for 16-weeks. Multivariate analysis shows that GFm colonized with microbiota from HFD-non-responder and quercetin supplemented-HFD donors (protected against NAFLD) clusters together, whereas GFm colonized with microbiota from control and HFD-responder mice (non-protected against NAFLD) establishes another cluster. Protected phenotype is associated with increased gut Desulfovibrio and Oscillospira, reduced gut Bacteroides and Oribacterium, lower primary and higher secondary BAs in plasma and feces, induction of hepatic BA transporters, and repression of hepatic lipogenic and BA synthesis genes. Conclusion: Protective gut microbiota associates with increased specific secondary BAs, which likely inhibit lipogenic pathways and enhance bile flow in the liver. This novel cross-talk between gut and liver, via plasma BAs, that promotes protection against NAFLD may have clinical and nutritional relevance, SI, P.D.P. and M.V.G.-M. share first authorship. S.S.-C. and R.J. share se-nior authorship. The authors thank Drs. G ́erard and Rabot, from MI-CALIS Institute (INRA), for providing germ-free mice. The authors wouldalso like to thank the Analytical Unit of Instituto de Investigaci ́on San-itaria La Fe, Valencia, for performing the bile acid profiling in plasmaand feces. This study has been funded by Instituto de Salud Carlos IIIthrough the project “PI17/01089” (cofounded by European Regional De-velopment Fund “A way to achieve Europe”) and by grants from Minis-terio de Econom ́ıa y Competitividad/Fondo Europeo de Desarrollo Re-gional (FEDER) (BFU2013-48141-R and BFU2017-87960-R) and Junta deCastilla y Le ́on/FEDER (LE063U16 and GRS1888/A/18). P.D.P. was sup-ported by Sara Borrell Postdoctoral Contract CD18/00158 from the Insti-tuto de Salud Carlos III, cofounded by the European Social Fund. D.P.was supported by a fellowship from Junta de Castilla y Le ́on cofinancedby the European Social Fund. E.N. was supported by Fundaci ́on de Inves-tigaci ́on Sanitaria of Le ́on. M.V.G.-M. was supported by CIBERehd con-tracts. CIBERehd is funded by the Instituto de Salud Carlos III, Spain
Proyecto:
ISCIII / Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia PI17
,
MINECO / Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia BFU2013-48141-R
,
AEI / Programa Estatal de I+D+i Orientada a los Retos de la Sociedad BFU2017-87960-R
DOI: https://onlinelibrary.wiley.com/doi/epdf/10.1002/mnfr.201900487, https://hdl.handle.net/10612/17920
HANDLE: https://onlinelibrary.wiley.com/doi/epdf/10.1002/mnfr.201900487, https://hdl.handle.net/10612/17920